Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3078966 | 0.84 | SMN1; SMN2 (0.40) | CASRSMN1; SMN2NPC1MAP4K1ALDH1A1 | |
| SCHEMBL3070127 | 0.82 | SMN1; SMN2 (0.35) | CASRSMN1; SMN2NPC1MAP4K1ALDH1A1 | |
| SCHEMBL3075854 | 0.82 | NPC1 (0.37) | SMN1; SMN2NPC1MAP4K1ALDH1A1MAPT | |
| SCHEMBL29117063 | 0.77 | TLR8 (0.38) | CASRSMN1; SMN2NPC1 | |
| SCHEMBL21684868 | 0.76 | CASR (0.35) | CASRNPC1F11MAP4K1 | |
| SCHEMBL21684696 | 0.72 | F11 (0.41) | NPC1F11MAP4K1MAPT | |
| SCHEMBL21685317 | 0.72 | VCP (0.37) | CASRNPC1F11 | |
| SCHEMBL21685429 | 0.72 | F11 (0.41) | SMN1; SMN2NPC1F11MAP4K1ALDH1A1 | |
| SCHEMBL21684454 | 0.71 | F11 (0.35) | CASRNPC1F11MAP4K1 | |
| SCHEMBL21684736 | 0.71 | CYP1A2 (0.36) | CASRNPC1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CASR 1270/4885SMN1; SMN2 4291/4885NPC1 794/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CASR 1270/4885SMN1; SMN2 4291/4885NPC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.